Valitacell is led by an experienced team with significant experience in the healthcare industry, in establishing and managing start-up companies, and in developing and concluding exclusive IVD supplier contracts to major multinational companies.
Terry McWade - cEO
Terry worked in the pharmaceutical industry with Servier Laboratories as Managing Director of Servier Denmark and previously in the Paris headquarters (1988-1992). He led the healthcare consulting practice in the London office of the Boston Consulting Group (1993-1999). As CEO of Exceptis Technologies, Terry led the sale of the business to Trintech Group (TTPA nasdaq) for $26m in 2000. Prior to establishing Valitacell Terry was Deputy CEO of the Royal College of Surgeons in Ireland (2002-2013). He is the former Chairman of the European Vaccine Initiative, Deputy Chairman of the Dublin Dental Hospital and serves on a number of committees of the Irish Medical Council. Terry trained as a medical doctor in Trinity College Dublin and holds an MBA from INSEAD.
jerry Clifford - COO
Prior to establishing Valitacell Jerry worked as the Commercial Director of Technopath Ltd (2010-2014). In this role he initiated and defined the research programme with the University of Sheffield which led to the development of the Valitacell technologies and the associated IP. The Technopath Group grew significantly during his time there, including achieving a sole supplier contract with a major IVD company. A trade-sale exit of Technopath Distribution to Diploma Healthcare followed in September 2014. Prior to Technopath Jerry was Vice President for Development at the Institute of Technology Tralee. He is a founder and a Non-Executive Director of Castel International, a provider of English Language and concierge services to a number of Irish universities and medical training colleges. Jerry trained as neuroscientist and holds a PhD from RCSI and an MBA from UCC.
david James - cSO
The Scientific Advisory Board for Valitacell is chaired by Prof. David James of the University of Sheffield. David graduated in 1989 from King ́s College London with a Ph.D. in Biochemistry, followed by postdoctoral research in Wye College (University of London), then the University of Kent; the latter a joint project with the Advanced Centre for Biochemical Engineering at University College London. He moved to the University of Queensland in 2001 as an Associate Professor of Bioengineering, then Professorial Research Fellow in the Australian Institute of Bioengineering and Nanotechnology. David was appointed Chair in Bioprocess Engineering at Sheffield in 2006 with a Royal Society Wolfson Research Merit Award "Research and Training in Biopharmaceutical Bioprocessing for UK Bioindustry".
Ben Thompson - Director of innovation
Ben is an extremely experienced cell line development scientist with a unique combination of education and expertise in bioprocess engineering, mathematics and statistics. Ben has been centrally involved in all Valitacell product innovations since inception and is a co- inventor of Valitacell IP.
carolanne Doherty - Marketing & Sales Manager
Carolanne is a design and sales focused scientist with a PhD in Molecular and Computational Biology spanning hypothesis testing in complex systems biology to rational impact dissemination of the results. Prior to joining Valitacell, Carolanne was the project manager with the School of Medicine UCD, developing health-tech apps to improve global primary healthcare in Africa and she led a pilot clinical study on type 2 diabetes in Malawi. Carolanne holds a PhD in Systems Biology from Systems Biology Ireland in University College Dublin, and an MSc in Science Communication from UWE in Bristol, UK.
Hannah Byrne - Product Manager
Hannah is a Product Manager at Valitacell responsible for developing the product strategy for ValitaTITER. Prior to joining Valitacell, Hannah held the position of Research Scientist at Kymab, a biotechnology company based in Cambridge U.K. During her time at Kymab, Hannah initially worked in technology development, where her main focus was on the construction of their bispecific antibody generation platform before making the transition into bio-analytics, formulation and project leadership. Hannah holds a PhD in Biochemistry from Dublin City University.
Karen Coss - Product Manager
Karen is a Product Manager at Valitacell, responsible for the development of the ValitaQC platform. Prior to joining Valitacell, Karen was a Research Associate at King’s College London, in the department of infectious diseases. During this time, Karen studied the glycosylation of HIV-1 during infection with an application towards vaccine design. Karen holds a PhD in Translational Medicine from University College Dublin, where she used genomic and glycomic approaches to develop antibody biomarkers to monitor patients with rare metabolic disorders.
Stephanie Davies - Product Development Specialist
Stephanie is a product development scientist working on the application of Valitacell technology into new areas, with particular focus on the ChemStress fingerprinting platform with application in cell therapy and exosome production. Stephanie holds a PhD in Molecular Cell Biology from University College Cork and has experience in design and optimisation of cell-based systems.
Jonathan Cawley - Product Development Scientist
Jonathan is a Product Development Scientist at Valitacell with a particular emphasis in enabling cell line selection based on desirable glycosylation profiles. Prior to joining Valitacell he completed his PhD in Biotechnology at Dublin City University. His thesis described the use of recombinant lectin probes for investigating CHO cell surface glycosylation. He is experienced in protein purification, CHO cell culture, molecular biology and glycan analysis. He co-authored a book chapter entitled ‘Lectin Affinity Chromatography’ published in 2017 in Protein Chromatography. He completed his PhD in 2017.
Paul Dobson - Data Scientist
Paul has wide-ranging experience at the interface between biotechnology, computer science and engineering. With a long track record of using informatics and modelling to advance the fundamental understanding of drug action and cell function, Paul applies his unique experience to drive drug discovery and Industrial Biotech cell and process design for biomanufacturing. He has worked in major interdisciplinary academic research groups and previously led his own biomanufacturing research group at The University of Sheffield.